Investigational Pipeline
Addiction & Mental Health
Compounds still inside company-run clinical trials, neither approved for any use nor sold by any vendor, including research-chemical or "research use only" sellers.
-
Brenipatide
Brenipatide (LY3537031) is Eli Lilly's investigational GIP/GLP-1 receptor agonist in phase 3 trials for alcohol use disorder and major depressive disorder, not weight loss. Phase 1 data showed GI side effects matching placebo. Not approved anywhere; never sold in any form.